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PEG-IFN for the treatment of hepatitis D 
Alessia Ciancio and Mario Rizzetto  
 
Currently, there is no satisfactory treatment for patients coinfected with hepatitis B virus and 
hepatitis D virus, which causes hepatitis D-the most severe form of hepatitis. A recent study 
has assessed the safety and efficacy of PEG-IFN-a2a and adefovir alone and in combination 
in these patients. 
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Hepatitis D is caused by the hepatitis D virus (HDV), a defective subviral pathogen that requires 
concomitant infection with the hepatitis B virus (HBV) to be infective. Although the double viral 
infection would seem to be more vulnerable to antiviral attacks than a single viral infection (as 
patients with the double infection have two distinct viral targets), chronic hepatitis D remains the 
most difficult to treat of the viral hepatitides. The minimalist HDV has no replicative machinery of 
its own; it is replicated by mammalian RNA polymerases and, therefore, does not encode specific 
enzymatic functions that can be targeted by antiviral agents.' Ongoing HDV infections inhibit the 
synthesis of the concomitant HBV, to the point that HBV DNA  
in the serum is often undetectable or barely detectable. Not surprisingly, attempts to use lamivudine 
to further inhibit and possibly eradicate the HBV, thus depriving the HDV of its biological 




The current treatment for patients with chronic hepatitis D remains empirical and still relies on 
interferon (IFN), which was first used in the 1980s and is the only drug licensed for the treatment of 
patients with this disease
3
. In the 19905, several studies showed that conventional IFN- provides  
some therapeutic efficacy in patients with chronic hepatitis D, with about 20% of the patients 
maintaining a biochemical and virological response 6 months after a 6-12 month course of therapy: 
however, these studies included small numbers of patients, the clinical features of the patients were 
heterogeneous and treatment protocols varied in the different series
3
. 
In the 2000s, the advent of PEG-IFNs and their increased efficacy compared with conventional 
IFNs further stimulated therapeutic interest in this group of drugs for the treatment of chronic 
hepatitis D. The initial experience with this therapy was obtained from the use of PEG- IFN-a2b.  
Treatment with this type of IFN induced rates of sustained virological responses that varied from 
17% to 43%4-6 However, these studies also included only a small number of patients and are 
difficult to compare because of the clinical heterogeneity of the patients; the highest rates of 
sustained virological response were reported in a series of 14 patients, most of whom did not have 
cirrhosis (a common complication in patients with HDV).
5
  
The paper by Wedemeyer and coworkers
7
 provides information on what can be achieved with PEG-
IFN-2a in patients infected with HBV and HDV. Wedemeyer et al. compared the efficacy of PEG- 
IFN-2a alone versus its combination with adefovir and adefovir monotherapy. They recruited  
90 patients; 31 were assigned to a 48-week therapy with 180 g per week of PEG-IFN-2a, plus 10 
mg per day of adefovir; 29 received PEG-IFN-2a only; 30 received adefovir only. This study is 
the largest on HDV therapy conducted to date.  
The primary outcome of the study (normal levels of alanine aminotransferasi and undetectable 
levels of HDV RNA at the end of therapy) was only obtained in 7% of the patients in each PEG- 
IFN-2a group. However, during therapy HDV RNA became undetectable in the serum of seven  
patients in each of the groups that received PEG-IFN-2a (23-24%) versus none in the adefovir 
monotherapy group; three patients lost the viral marker during follow-up after completion of the 
therapy, bringing the overall figure for viral clearance to 28% in the treatment arms that used  
PEG-IFN-2a.  
The data from this well-designed and well-conducted trial in a reasonably large number of 
patients who have HDV indicate that HDV can be controlled with PEG- IFN-2a in almost 30% of 
patients. However, adefovir, which is active against HBV, was not efficacious either alone or in  
combination with PEG-IFN-2a.  
In all patients, the adverse events were acceptable and not different from those expected with 
PEG-IFN monotherapy. Liver disease in one patient with a low platelet count, and presumably 
advanced cirrhosis, decompensated during therapy, which emphasizes the need to carefully select  
patients with HDV for PEG-IFN therapy, as many of these patients have cirrhosis by the time of 
clinical presentation.  
In this study, as in previous studies, 
4,6
 the pattern of HDV RNA expression during therapy was 
somewhat inconsistent. Relapses occurred in patients who had cleared HDV RNA while on therapy 
and viral clearance was observed during the follow-up in patients who had detectable levels of 
HDV RNA at the end of therapy. The predictability of a patient's response; therefore, seems to be 
an issue with this therapy and a period of treatment longer than 48 weeks could be considered as  
standard protocol.  
Although the results of this study indicate that PEG-IFN-2a can induce remission of viremia in a 
considerable proportion of patients with chronic hepatitis D, the ultimate clinical meaning of this 
therapeutic success remains unclear. No notable histological amelioration was found in paired  
biopsy samples, in fact fibrosis and histological activity scores worsened in a proportion of patients 
given PEG- IFN-2a, and the levels of alanine aminotransferase also normalized in patients who 
had detectable levels of HDV RNA throughout the follow-up.  
In the context of HBV infection, HDV remains infectious and ready to reactivate even when the 
virus is at very low levels
8
. The infectious potential of HDV will probably remain high even in 
patients who have numbers of viral copies in their serum well below the 120 copies per ml that 
represented the lower limit of HDV RNA detection of the analytical test used in the study by 
Wedemeyer and colleagues. Thus, it is uncertain whether not detecting HDV RNA 6 months after 
.therapy in the presence of hepatitis B surface antigen (HBsAg) does in fact indicate a change in the 
natural history of chronic hepatitis D represents an ephemeral event with no long-term clinical 
effects. Only anecdotal reports exist of long-term clinical ameliorations after treatment with IFN
9
 
and longitudinal retrospective surveys of previously treated patients are needed to establish the true 
clinical value of the current IFN therapy in patients with chronic hepatitis D.  
The relevance of HBsAg to the therapeutic outcome was addressed by Wedemeyer and 
colleagues. They determined the decline of HBsAg induced in the three treatment arms and found 
that only the combination of PEG-IFN-2a with adefovir resulted in a considerable decline in the 
levels of the antigen in serum; the HBsAg level diminished by at least l log10, IU/ml in 
approximately one-third of patients who received combination therapy. This finding points to a 
more incisive approach to therapy for patients with hepatitis D. This approach would involve the 
combination of drugs, such as PEG-IFN with adefovir, which are able not only to diminish HDV 
RNA synthesis but also to interfere with the synthesis of the HBsAg or to change its structure; 
modifications of the HBsAg could block hepatitis D virion assembly and prevent HDV reinfection 
in new hepatocytes
1
. Current efforts to manipulate HBsAg such that it can no longer attach to 
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